Announcement PDF ASX Announcement | 14 December 2023 AdAlta Limited (ASX:1AD) Results of Extraordinary General Meeting AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body® platform advises that its Extraordinary General Meeting was held today at 11:00am AEDT. In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary. All resolutions were carried with support of more than 93% of shares voted. This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD). For further information, please contact: AdAlta Limited (ASX:1AD) Tim Oldham CEO & Managing Director P: +61 3 9479 5159 E: t.oldham@adalta.com.au Media & Investor Enquiries The Capital Network Julia Maguire P: +61 2 8999 3699 E: julia@thecapitalnetwork.com.au To ask questions about, or comment on, this release, please visit AdAlta’s Investor Hub: https://investorhub.adalta.com.au/link/MrDEQP About AdAlta Limited AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials. AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation. AdAlta Limited (ASX:1AD) 15/2 Park Drive, Bundoora 3083 Victoria Australia ABN: 92 120 332 925 www.adalta.com.au 1 The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development. AdAlta’s strategy is to maximise the products developed using its next generation i-body® platform by internally discovering and developing selected i-body® enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats. For more information To learn more, please visit: www.adalta.com.au 2 Disclosure of Proxy Votes Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 AdAlta Limited Extraordinary General Meeting Thursday, 14 December 2023 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Poll Results (if applicable) Proxy Votes Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed 1 Ratification of prior issue of Shares and Options P 200,980,770 2 Approval of issue of Additional Options P 200,980,770 3 Approval of issue of Shares and Options to an entity associated with Dr Timothy Oldham, a Director of the Company P 275,922,705 4 Approval of issue of oversubscriptions for Shares and Options P 136,668,278 5 Approval of issue of Options to Peak Asset Management P 274,069,437 FOR AGAINST 193,812,098 6,928,672 96.43% 3.45% 192,477,227 8,263,543 95.77% 4.11% 267,407,942 8,274,763 96.91% 3.00% 128,214,735 8,213,543 93.81% 6.01% 261,943,190 8,213,543 95.58% 3.00% ABSTAIN 3,630,000 3,630,000 1,131,750 30,000 30,000 PROXY'S DISCRETION FOR AGAINST 240,000 194,820,004 6,928,672 0.12% 96.57% 3.43% 240,000 193,485,133 8,263,543 0.12% 95.90% 4.10% 240,000 268,415,848 8,274,763 0.09% 97.01% 2.99% 240,000 129,222,641 8,213,543 0.18% 94.02% 5.98% 3,912,704 266,623,800 8,213,543 1.43% 97.01% 2.99% Results ABSTAIN OUTCOME 3,630,000 Passed 3,630,000 Passed 1,131,750 Passed 30,000 Passed 30,000 Passed